Hot Safest Stocks To Watch For 2019

tags:CIR,SUPV,AWR,ITOT, Gold doesn't trade in a vacuum.   Markets are connected. What happens in one often affects others.   So if you want to understand what's happening with gold, you need to know what's going on in the markets that affect gold.   And while lots of traders focus only on the short term, it's important to have a big-picture view, too. The big picture shows you the long-term trends at work... and when they change. It can help you find low-risk opportunities to open new positions. And it can help you determine where to set your stops.   Today, we'll look at the big picture for two markets that affect gold... along with gold itself.   Let's get started...   The first market we'll look at is U.S. government bonds... specifically, the yield on 10-year U.S. Treasurys. The U.S. government is considered the world's safest borrower. (It can print money to pay lenders back, after all.) The rate it pays to borrow money for 10 years serves as the world's benchmark interest rate.

Hot Safest Stocks To Watch For 2019: CIRCOR International, Inc.(CIR)

Advisors' Opinion:

• [By Max Byerly]

  CIRCOR International (NYSE: CIR) and ARC Group WorldWide (NASDAQ:ARCW) are both small-cap industrial products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on CIRCOR International (CIR)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on CIRCOR International (CIR)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Stephan Byrd]

  Peel Hunt reaffirmed their hold rating on shares of Circassia Pharmaceuticals (LON:CIR) in a report published on Thursday.

  A number of other research analysts have also recently commented on the company. Numis Securities decreased their price target on Circassia Pharmaceuticals from GBX 180 ($2.42) to GBX 140 ($1.88) and set a buy rating on the stock in a research report on Tuesday, April 24th. JPMorgan Chase & Co. restated a neutral rating on shares of Circassia Pharmaceuticals in a research report on Tuesday, April 24th.

Hot Safest Stocks To Watch For 2019: Grupo Supervielle S.A. (SUPV)

Advisors' Opinion:

• [By Logan Wallace]

  Mckinley Capital Management LLC Delaware lowered its holdings in Grupo Supervielle (NYSE:SUPV) by 19.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 33,744 shares of the company’s stock after selling 7,984 shares during the quarter. Mckinley Capital Management LLC Delaware’s holdings in Grupo Supervielle were worth $1,023,000 as of its most recent SEC filing.

• [By Logan Wallace]

  Credicorp (NYSE: BAP) and Grupo Supervielle (NYSE:SUPV) are both finance companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

• [By Logan Wallace]

  Grupo Supervielle (NYSE:SUPV) shares dropped 4.7% on Monday . The company traded as low as $13.96 and last traded at $12.98. Approximately 30,924 shares were traded during trading, a decline of 97% from the average daily volume of 1,141,060 shares. The stock had previously closed at $13.62.

Hot Safest Stocks To Watch For 2019: American States Water Company(AWR)

Advisors' Opinion:

• [By Neha Chamaria]

  Contrary to what many believe, it's easier to find stocks to invest in when you're in your 60s. That's because your choices narrow down significantly as you filter out young, aggressive companies that typically carry higher risk. As you near retirement, you need a portfolio choc-a-block with mature, established businesses that have a visible growth path and preferably offer solid dividends to supplement your income. Three interesting stocks that fit the bill are American States Water (NYSE:AWR), A.O. Smith (NYSE:AOS), and Realty Income (NYSE:O).

• [By Reuben Gregg Brewer]

  American States Water Company (NYSE:AWR) has increased its dividend each and every year for 63 consecutive years. That's a feat unmatched by its water utility rivals, and most other companies for that matter. But that incredible run of dividend hikes doesn't mean that American States is a good investment. Here's the background you need in order to make a better call here.� �

• [By Neha Chamaria]

  In terms of dividend growth, only four of the above stocks -- 3M, Colgate-Palmolive, Coca-Cola, and Procter & Gamble -- feature among the 10 fastest dividend-growth kings. In other words, there are six other stocks from the dividend kings list that have grown their dividends at a faster pace than most stocks in the above table in the past decade, some even at double-digits.��

  Six top dividend kings by dividend growth Dividend King 10-Year Dividend CAGR Current Dividend Yield Payout Ratio (TTM) Lowe's Companies� 18.5% 2% 34.5% Hormel Foods� 16.3% 2.1% 39.2% Parker-Hannifin Corp�(NYSE:PH) 14% 1.7% 35.2% Nordson Corporation� 12.2% 0.9% 13.3% Dover Corp (NYSE:DOV) 9% 2% 37.4% American States Water�(NYSE:AWR) 7.6% 1.9% 54.8%

  TTM: Trailing 12 months. Data sources: YCharts and Yahoo! Finance. Table by author.

• [By Stephan Byrd]

  AWARE (CURRENCY:AWR) traded 3.3% lower against the U.S. dollar during the 24-hour period ending at 9:00 AM E.T. on June 5th. During the last week, AWARE has traded down 0.7% against the U.S. dollar. One AWARE token can now be bought for about $0.0294 or 0.00000396 BTC on major cryptocurrency exchanges including BigONE, Bibox and Allcoin. AWARE has a total market cap of $0.00 and $1.37 million worth of AWARE was traded on exchanges in the last 24 hours.

Hot Safest Stocks To Watch For 2019: iShares Core S&P Total US Stock Mkt (ITOT)

Advisors' Opinion:

• [By Todd Shriber, ETF Professor]

  Hundreds of exchange traded funds offer investors broad market exposure and many do so with nominal fees. Among the least expensive is the iShares Core S&P Total U.S. Stock Market ETF (NYSE: ITOT).

Top 10 Biotech Stocks To Buy For 2019

tags:ALNY,AMGN,BIIB,ARQL,

By Paul Lebo, CFA and Greg Wilkins

Athersys Inc.

Athersys Incorporated (Ticker: ATHX) is a biotechnology company that is focused primarily in the field of regenerative medicine and is committed to the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life. ATHX has established a portfolio of therapeutic product development programs to address significant unmet medical needs in multiple disease areas. Their lead project that has the most potential is MultiStem cell therapy, a patented and proprietary allogeneic stem cell product, with several clinical stage programs. ATHX��s current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients. These represent major areas of clinical need, as well as substantial commercial opportunities and ATHX is pursuing opportunities in several potential multi-billion dollar markets.

Top 10 Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:

• [By Brian Orelli]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

• [By Keith Speights]

  I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick -- but with a couple of qualifications. First, I didn't think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

• [By Max Byerly]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

Top 10 Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors' Opinion:

• [By Keith Speights]

  It's not too hard to find biotech stocks that are bargains right now. Two of the most attractively priced biotech stocks on the market are Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD). Both stocks also provide nice dividend yields for income-seeking investors.

• [By Jon C. Ogg]

  In September of 2016, Amgen Inc. (NASDAQ: AMGN) announced that the FDA had approved its Amjevita as a biosimilar to Humira for multiple inflammatory diseases that included RA and several other related inflammatory diseases.

• [By Chris Lange]

  Amgen Inc. (NASDAQ: AMGN) shares made a slight gain on Tuesday after it was announced that the U.S. Food and Drug Administration (FDA) approved its treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture. Specifically, the agency approved Prolia (denosumab), driven by positive late-stage results.

Top 10 Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors' Opinion:

• [By Brian Orelli]

  Data source: Ionis Pharmaceuticals.

  What happened with Ionis Pharmaceuticals this quarter? Revenue increased thanks to $41 million in royalties from Biogen's (NASDAQ:BIIB) sales of Spinraza, up from just $5 million in the year-ago quarter. Because the tiered royalty rates reset each year, the royalties as a percentage of sales will end up being higher in the quarters to come this year. Despite the higher revenue, earnings turned negative on a GAAP (generally accepted accounting principles) basis: Ionis and Akcea Therapeutics (NASDAQ:AKCA) increased spending in preparation for the launch of Tegsedi for hereditary transthyretin amyloidosis (hATTR), and Waylivra for familial chylomicronemia syndrome, a rare disease that causes the buildup of lipids. Ionis is still the majority owner of Akcea, so its financials are incorporated into Ionis' financials. The Food and Drug Administration pushed back its goal for making a decision on the marketing application for Tegsedi (the new brand name for inotersen) to Oct. 6, 2018. Ionis provided additional data analysis that the FDA needs additional time to review. In April, Ionis signed another deal with Biogen to develop antisense drugs for neurological disorders. In the deal, Ionis gets $1 billion up front, including an equity investment, in exchange for Biogen having first choice of neurology targets on which to exclusively collaborate with Ionis. Biogen is paying for everything beyond the initial discovery stage, with Ionis eligible for royalties and milestone payments as the drugs advance.

  Image source: Getty Images.

• [By Brian Orelli]

  Drug-developer Biogen (NASDAQ:BIIB) reported a pretty strong earnings�increase in the first quarter. While revenue growth wasn't as solid, investors appear to be giving management a pass, thanks to its explanations on why slowing first-quarter sales aren't a sign of future trouble.

• [By Lisa Levin] Companies Reporting Before The Bell United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion. The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion. Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion. Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion. Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion. The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion. Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion. 3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion. JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion. Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion. Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion. Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion. Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion. The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion. Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion. PACCAR Inc (NASDAQ: PCAR) is projected to
• [By Dan Caplinger]

  Wall Street continued its downward streak on Monday, with the Dow Jones Industrial Average falling more than 100 points. Most major benchmarks fell more modestly, with a few actually poking into positive territory on the day. Trade-sensitive stocks were among the weakest as investors focused on uncertainty related to tariff disputes between the U.S. and China. But for some other companies, bad news of a different sort was responsible for the drops in their shares. Biogen (NASDAQ:BIIB), Baytex Energy (NYSE:BTE), and Catalyst Biosciences (NASDAQ:CBIO) were among the worst performers on the day. Here's why they did so poorly.

• [By Todd Campbell]

  Unfortunately for investors, June's discovery wasn't exciting enough for Sangamo partners Biogen (NASDAQ:BIIB) and Shire (NASDAQ:SHPG). In 2015, Biogen announced a delay to its beta-thalassemia and sickle-cell disease treatment program with Sangamo. And then Shire, a Sangamo collaboration partner since 2012, walked away from Sangamo's hemophilia program.

Top 10 Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors' Opinion:

• [By Ethan Ryder]

  ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on ArQule (ARQL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Maxx Chatsko]

  Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning.�

• [By Logan Wallace]

  BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

  A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.